Page last updated: 2024-08-17

acetyl coenzyme a and Hematologic Malignancies

acetyl coenzyme a has been researched along with Hematologic Malignancies in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Algire, M; Bromberg, KD; Buchanan, FG; Chiang, GG; Choudhary, C; Cole, PA; de Vries, P; Digiammarino, EL; Edalji, RP; Faivre, E; Ferguson, D; Frey, R; Hansen, TM; Hessler, P; Jakob, CG; Karukurichi, K; Kesicki, E; Lai, A; Lam, LT; Langston, JW; Lasko, LM; Manaves, V; Marmorstein, R; Martin, RL; McElligott, D; Michaelides, MR; Montgomery, D; Qiu, W; Risi, RM; Rosenberg, SH; Shaw, B; Sun, C; Torrent, M; Uziel, T; Van Drie, JH; Weinert, BT1

Other Studies

1 other study(ies) available for acetyl coenzyme a and Hematologic Malignancies

ArticleYear
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
    Nature, 2017, 10-05, Volume: 550, Issue:7674

    Topics: Acetyl Coenzyme A; Animals; Antineoplastic Agents; Binding, Competitive; Biocatalysis; Catalytic Domain; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Crystallography, X-Ray; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Heterocyclic Compounds, 4 or More Rings; Histone Acetyltransferases; Humans; Male; Mice; Mice, SCID; Models, Molecular; Neoplasms; p300-CBP Transcription Factors; Prostatic Neoplasms, Castration-Resistant; Protein Conformation; Receptors, Androgen; Xenograft Model Antitumor Assays

2017